Researchers in Dr. Fan Yang's lab have developed 3D tissue engineering scaffolds with dynamic, temporally and spatially controllable macropore formation.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.
Stanford and Rockefeller researchers have identified and developed dynein-specific inhibitors that have significant medical applications involving mitotic spindle assembly, organelle transport, and primary cilia formation.
Researchers in Dr. Michael Cleary's laboratory at Stanford University have developed a highly specific monoclonal antibody for AF5, a proto-oncoprotein associated with pediatric and adult acute leukemia.
A method of using neuregulin antagonists to delay the time of tumor recurrence in cancer patients has been developed by Dr. Sweet-Cordero and collaborators. This technology is available for non-exclusive license.
Researchers in Dr. Laura Attardi's lab have created a knock-in mouse strain which generates a form of p53 that is not subject to degradation by the proteasome.
A team of Stanford researchers has developed a novel method for quickly and efficiently generating human induced pluripotent stem cells (hiPSCs) using human adipose stem cells (hASCs) as the starting population.
A team of Stanford researchers have developed a simple, novel, non-viral technique for generating human induced pluripotent stem cells (hiPSCs) with minicircle DNA. This technology uses a single minicircle vector that expresses four reprogramming factors.
Rat monoclonal antibody BZ194 specifically recognizes mouse serpentine receptor mCMKLR1 (aka ChemR23, DEZ). mCMKLR1 is a novel protein possessing high homology with members of the chemoattractant receptor family, and binds the chemoattractant chemerin.
This mouse model of phosphodiesterase deficiency was developed using homologous recombination to knock-out the gene for PDE4D. The mice have a null PDE4D gene on C57BL/6 x 129/OLA background. These mice have proven useful in studies of asthma (see publications).
This mouse model of phosphodiesterase deficiency was developed using homologous recombination to knock-out the gene for PDE4B. The mice have a null PDE4B gene on C57BL/6 x 129/OLA background.
There are two aspects to this invention, the RetroTet-ART vectors themselves, and the use of those vectors to identify novel regulatory elements (untranslated regions, or UTR's).